The role of white and grey matter and meningeal inflammation in multiple sclerosis (MS) and clinically isolated syndromes (CIS) as quantified using [(11)C](R)-PK11195 positron emission tomography (PET) scanning
Phase 1
- Conditions
- Multiple SclerosisMedDRA version: 9.1Level: HLTClassification code 10052785Term: Multiple sclerosis acute and progressive
- Registration Number
- EUCTR2007-007394-22-GB
- Lead Sponsor
- Imperial College London
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 99999
Inclusion Criteria
Patients must have a confirmed diagnosis of multiple sclerosis or clinically isolated syndrome
Age 18-65
Able to give written informed consent
Subjects fulfil NICE criteria for use of natalizumab (NICE, 2007)
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years)
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years)
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Unable to give informed consent
Primary progressive MS
Patient unable to tolerate MRI scan or PET scan
Those that have experienced a relapse or have been treated with steroids (both i.v. and oral) within 1 month.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method